Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR⁺/HER2^- breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

ABSTRACT:

Background

Advanced breast cancer (ABC) is characterized by multidimensional clinical complexity that is usually not considered in randomized clinical trials. In the present real-life study, we investigated the link between clinical complexity and quality of life of patients with HR⁺/HER2^- ABC treated with CDK4/6 inhibitors.

Methods

We evaluated multimorbidity burden assessed with the Cumulative Illness Rating Scale (CIRS), polypharmacy and patient-reported outcomes (PROs). PROs were assessed at baseline (T0), after 3 months of therapy (T1), and at disease progression (T2) using EORTC QLC-C30 and QLQ-BR23 questionnaires. Baseline PROs and changes between T0 and T1 were evaluated amongst patients with different multimorbidity burden (CIRS <5 and ≥5) and

SUBMITTER: Tagliaferri B 

PROVIDER: S-EPMC10291968 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature